INNOGENE Co.,Ltd. (KOSDAQ:344860)
South Korea · Delayed Price · Currency is KRW 1,299.00
-78.00 (-5.66%)
At close: Oct 2, 2026
INNOGENE Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 11,938 | 8,213 | 8,945 | 10,101 | 9,139 | 9,385 |
Revenue Growth | 56.46% | -8.17% | -11.45% | 10.52% | -2.62% | 66.29% |
Gross Profit Gross Profit Growth | 6,232 | 6,190 | 6,620 | 7,320 | 6,776 | 7,316 |
Operating Income Operating Income Growth | -626.19 | -65.51 | 630.49 | 1,226 | 1,488 | 2,399 |
Net Income Net Income Growth | -297.67 | 287.88 | 945.16 | 1,396 | 1,339 | 2,258 |
Earnings Per Share EPS Growth | -24.25 | 25.50 | 79.00 | 120.00 | 144.00 | 243.00 |
EPS Growth | - | -67.72% | -34.17% | -16.67% | -40.74% | - |
| Fiscal Year | FY 2024 | FY 2023 |
|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Cosmetics and Medical Devices Product Cosmetics and Medical Devices Product Growth | 7,565 | 8,928 |
Cosmetics and Medical Devices Commodity Cosmetics and Medical Devices Commodity Growth | 1,379 | 1,173 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 7,203 | 10,674 | 13,488 | 13,143 | 3,235 | 2,813 |
Total Debt Total Debt Growth | 128.96 | 99.54 | 74.95 | 140.12 | 159.34 | 170.83 |
Net Cash (Debt) Net Cash Growth | 7,074 | 10,574 | 13,413 | 13,003 | 3,076 | 2,643 |
Net Cash Growth | -34.79% | -21.17% | 3.15% | 322.71% | 16.40% | - |
Net Cash Per Share Net Cash Per Share Growth | 576.28 | 936.67 | 1121.11 | 1117.61 | 330.73 | 284.43 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -967.26 | 704.37 | 809.15 | 2,236 | 584.64 | 2,173 |
Capital Expenditures CapEx Growth | -186.18 | -152.28 | - | -47.84 | -34.4 | -4.81 |
Free Cash Flow Free Cash Flow Growth | -1,153 | 552.09 | 809.15 | 2,188 | 550.24 | 2,168 |
Free Cash Flow Growth | - | -31.77% | -63.02% | 297.69% | -74.62% | 403.97% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 52.20% | 75.37% | 74.01% | 72.47% | 74.14% | 77.95% |
Operating Margin | -5.24% | -0.80% | 7.05% | 12.14% | 16.28% | 25.56% |
Pretax Margin | -2.53% | 3.12% | 12.56% | 16.89% | 16.91% | 25.96% |
Profit Margin | -2.49% | 3.50% | 10.57% | 13.82% | 14.65% | 24.06% |
FCF Margin | -9.66% | 6.72% | 9.05% | 21.66% | 6.02% | 23.10% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | 77.89 | 18.85 | 23.61 | 30.59 | 18.51 |
P/FCF Ratio | - | 40.62 | 22.02 | 15.06 | 74.45 | 19.28 |
PS Ratio | 1.57 | 2.73 | 1.99 | 3.26 | 4.48 | 4.45 |